AOD9604 is a modified fragment of human growth hormone (hGH 176–191) developed to study lipolytic properties of GH without its growth-promoting or diabetogenic effects.
AOD9604 is a synthetic peptide corresponding to residues 176–191 of human growth hormone (hGH), with the addition of a tyrosine residue at the N-terminus. It was originally developed by researchers at Monash University with the goal of isolating the fat-metabolism activity of hGH from its growth-promoting and insulin-desensitizing properties. The compound has been studied in both preclinical models and early-phase clinical trials.
AOD9604 is proposed to exert its lipolytic effects through mechanisms independent of the IGF-1 pathway, which mediates much of GH's anabolic activity. Preclinical research suggests the compound stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) in adipocyte cultures and obese rodent models, without significantly affecting insulin sensitivity or blood glucose levels — a notable distinction from full-length hGH.
AOD9604 received GRAS (Generally Recognized as Safe) designation from the FDA in 2014 based on available safety data, though this designation pertains specifically to food additive use and does not constitute therapeutic approval. Current research interest focuses primarily on understanding the structure-activity relationship of hGH's C-terminal domain. NuvoTide supplies AOD9604 for in-vitro research use only.
For in-vitro research use only. Not for human or veterinary use.